- The U.S. Food and Drug Administration (FDA) granted fast track designation to Icosavax ( NASDAQ: ICVX ) bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate IVX-A12 for older adults 60 years of age and above.
- "IVX-A12 is differentiated as the most advanced vaccine candidate against these two leading causes of pneumonia in older adults," said Icosavax Chief Medical Officer Niranjan Kanesa-thasan.
- The company expects to report topline interim results from a phase 1 trial of IVX-A12 in mid-2023. Icosavax also plans to start a phase 2 trial of the vaccine in H2 2023.
- The company noted that it uses its virus-like particle (VLP) platform technology to develop vaccines.
- ICVX +6.39% to 9.65 premarket Feb. 21
For further details see:
Icosavax stock rises on FDA fast track status for bivalent RSV, hMPV vaccine IVX-A12